Iberdomide

Iberdomide
Clinical data
Trade namesZenbexus
Other namesCC-220
AHFS/Drugs.comzenbexus
License data
Routes of
administration
By mouth
Drug classCereblon-modulating protein degrader
ATC code
  • None
Legal status
Legal status
Identifiers
  • (3S)-3-[7-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC25H27N3O5
Molar mass449.507 g·mol−1
3D model (JSmol)
  • O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1

  • as HCl: Cl.O=C1N(CC2=C1C=CC=C2OCC3=CC=C(CN4CCOCC4)C=C3)[C@H]5CCC(=O)NC5=O
  • InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1
  • Key:IXZOHGPZAQLIBH-NRFANRHFSA-N

  • as HCl: InChI=1S/C25H27N3O5.ClH/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27;/h1-7,21H,8-16H2,(H,26,29,30);1H/t21-;/m0./s1
  • Key:VVHQVXXPZDALDV-BOXHHOBZSA-N

Iberdomide, sold under the brand name Zenbexus, is an anti-cancer medication used for the treatment of multiple myeloma. It is a cereblon-modulating protein degrader and a thalidomide analog.. It is taken by mouth.

Iberdomide was approved for medical use in the United States in August 2026.